SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
Tesla Launches New Model Y Variant in the US Starting at $41,990 
CAMBRIDGE, Mass., May 31, 2017 -- 2X Oncology, Inc. ("2X" or the "Company"), a company focused on developing targeted therapeutics to address significant unmet needs in women’s cancer, today announced that its chief executive officer, George O. Elston, will present at the Jefferies 2017 Global Healthcare Conference on Friday, June 9 at 10:00 am EDT.
The 2X presentation will be webcast live and archived for 90 days on the Company’s website under the ‘News’ tab.
Mr. Elston will be joined by other members of the executive team for a breakout session immediately after the presentation, and for one-on-one meetings throughout the conference. Please contact your Jefferies representative or Amy Raskopf to schedule a meeting with 2X.
About 2X Oncology
2X Oncology Inc. is a is a clinical stage company developing targeted therapeutics that leverage proprietary Drug Response Predictor (DRP™) companion diagnostic technology to address significant unmet needs in women’s cancer. The DRP generates a precision mRNA-based companion diagnostic for each compound, enabling the identification of patients that are most likely to respond and benefit from treatment.
The 2X pipeline includes product candidates focused on breast, ovarian, and endometrial cancers and primary and secondary brain tumors. These programs have shown clinical efficacy and safety and are positioned to enter focused Phase 2 studies with data expected in 2018.
A Cambridge, MA based spin-out from Oncology Venture ApS, 2X works in close collaboration with Oncology Venture and leverages its Danish registry of over 1,100 cancer patients for initial clinical studies. Learn more at 2xoncology.com.
DRP™ is a trademark of Medical Prognosis Institute A/S.
Contact
Amy Raskopf
+1 917.673.5775
[email protected]
www.2xoncology.com
Twitter: @2xoncology
